128 related articles for article (PubMed ID: 9361295)
1. Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease.
Björklund A; Rosenblad C; Winkler C; Kirik D
Neurobiol Dis; 1997; 4(3-4):186-200. PubMed ID: 9361295
[TBL] [Abstract][Full Text] [Related]
2. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model.
Rosenblad C; Kirik D; Björklund A
Exp Neurol; 2000 Feb; 161(2):503-16. PubMed ID: 10686072
[TBL] [Abstract][Full Text] [Related]
3. Dopamine D1 and D2 receptor-mediated acute and long-lasting behavioral effects of glial cell line-derived neurotrophic factor administered into the striatum.
Kobayashi S; Ogren SO; Hoffer BJ; Olson L
Exp Neurol; 1998 Dec; 154(2):302-14. PubMed ID: 9878169
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat.
Connor B; Kozlowski DA; Schallert T; Tillerson JL; Davidson BL; Bohn MC
Gene Ther; 1999 Dec; 6(12):1936-51. PubMed ID: 10637445
[TBL] [Abstract][Full Text] [Related]
5. Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor.
Choi-Lundberg DL; Lin Q; Schallert T; Crippens D; Davidson BL; Chang YN; Chiang YL; Qian J; Bardwaj L; Bohn MC
Exp Neurol; 1998 Dec; 154(2):261-75. PubMed ID: 9878166
[TBL] [Abstract][Full Text] [Related]
6. Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration.
Connor B; Kozlowski DA; Unnerstall JR; Elsworth JD; Tillerson JL; Schallert T; Bohn MC
Exp Neurol; 2001 May; 169(1):83-95. PubMed ID: 11312561
[TBL] [Abstract][Full Text] [Related]
7. Functional reinnervation from remaining DA terminals induced by GDNF lentivirus in a rat model of early Parkinson's disease.
Brizard M; Carcenac C; Bemelmans AP; Feuerstein C; Mallet J; Savasta M
Neurobiol Dis; 2006 Jan; 21(1):90-101. PubMed ID: 16084732
[TBL] [Abstract][Full Text] [Related]
8. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle.
Rosenblad C; Kirik D; Devaux B; Moffat B; Phillips HS; Björklund A
Eur J Neurosci; 1999 May; 11(5):1554-66. PubMed ID: 10215908
[TBL] [Abstract][Full Text] [Related]
9. Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease.
Wang L; Muramatsu S; Lu Y; Ikeguchi K; Fujimoto K; Okada T; Mizukami H; Hanazono Y; Kume A; Urano F; Ichinose H; Nagatsu T; Nakano I; Ozawa K
Gene Ther; 2002 Mar; 9(6):381-9. PubMed ID: 11960314
[TBL] [Abstract][Full Text] [Related]
10. Glial cell line-derived neurotrophic factor prevents death, but not reductions in tyrosine hydroxylase, of injured nigrostriatal neurons in adult rats.
Lu X; Hagg T
J Comp Neurol; 1997 Nov; 388(3):484-94. PubMed ID: 9368855
[TBL] [Abstract][Full Text] [Related]
11. Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections.
Kozlowski DA; Connor B; Tillerson JL; Schallert T; Bohn MC
Exp Neurol; 2000 Nov; 166(1):1-15. PubMed ID: 11031079
[TBL] [Abstract][Full Text] [Related]
12. Protection of dopaminergic nigrostriatal afferents by GDNF delivered by microspheres in a rodent model of Parkinson's disease.
Gouhier C; Chalon S; Aubert-Pouessel A; Venier-Julienne MC; Jollivet C; Benoit JP; Guilloteau D
Synapse; 2002 Jun; 44(3):124-31. PubMed ID: 11954043
[TBL] [Abstract][Full Text] [Related]
13. Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease.
Rosenblad C; Martinez-Serrano A; Björklund A
Neuroscience; 1998 Jan; 82(1):129-37. PubMed ID: 9483509
[TBL] [Abstract][Full Text] [Related]
14. In vivo protection of nigral dopamine neurons by lentiviral gene transfer of the novel GDNF-family member neublastin/artemin.
Rosenblad C; Grønborg M; Hansen C; Blom N; Meyer M; Johansen J; Dagø L; Kirik D; Patel UA; Lundberg C; Trono D; Björklund A; Johansen TE
Mol Cell Neurosci; 2000 Feb; 15(2):199-214. PubMed ID: 10673327
[TBL] [Abstract][Full Text] [Related]
15. Effects of 6-hydroxydopamine on primary cultures of substantia nigra: specific damage to dopamine neurons and the impact of glial cell line-derived neurotrophic factor.
Ding YM; Jaumotte JD; Signore AP; Zigmond MJ
J Neurochem; 2004 May; 89(3):776-87. PubMed ID: 15086533
[TBL] [Abstract][Full Text] [Related]
16. Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease?
Lindvall O; Wahlberg LU
Exp Neurol; 2008 Jan; 209(1):82-8. PubMed ID: 17963752
[TBL] [Abstract][Full Text] [Related]
17. The effect of GDNF on nigrostriatal dopaminergic function in response to a two-pulse K(+) stimulation.
Xu K; Dluzen DE
Exp Neurol; 2000 Dec; 166(2):450-7. PubMed ID: 11085910
[TBL] [Abstract][Full Text] [Related]
18. Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's disease.
Mandel RJ; Snyder RO; Leff SE
Exp Neurol; 1999 Nov; 160(1):205-14. PubMed ID: 10630205
[TBL] [Abstract][Full Text] [Related]
19. Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease.
Lo Bianco C; Déglon N; Pralong W; Aebischer P
Neurobiol Dis; 2004 Nov; 17(2):283-9. PubMed ID: 15474365
[TBL] [Abstract][Full Text] [Related]
20. Continuous exposure to glial cell line-derived neurotrophic factor to mature dopaminergic transplants impairs the graft's ability to improve spontaneous motor behavior in parkinsonian rats.
Winkler C; Georgievska B; Carlsson T; Lacar B; Kirik D
Neuroscience; 2006 Aug; 141(1):521-31. PubMed ID: 16697115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]